- Home
- UCAR vs CANF Comparison
UCAR vs CANF Comparison
Compare UCAR & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCAR
- CANF
- Stock Information
- Founded
- UCAR 2013
- CANF 1994
- Country
- UCAR China
- CANF Israel
- Employees
- UCAR N/A
- CANF N/A
- Industry
- UCAR Retail-Auto Dealers and Gas Stations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- UCAR Consumer Discretionary
- CANF Health Care
- Exchange
- UCAR Nasdaq
- CANF Nasdaq
- Market Cap
- UCAR 8.8M
- CANF 9.6M
- IPO Year
- UCAR 2023
- CANF N/A
- Fundamental
- Price
- UCAR $1.99
- CANF $0.63
- Analyst Decision
- UCAR
- CANF Strong Buy
- Analyst Count
- UCAR 0
- CANF 2
- Target Price
- UCAR N/A
- CANF $14.00
- AVG Volume (30 Days)
- UCAR 56.4K
- CANF 140.0K
- Earning Date
- UCAR 10-07-2025
- CANF 08-26-2025
- Dividend Yield
- UCAR N/A
- CANF N/A
- EPS Growth
- UCAR N/A
- CANF N/A
- EPS
- UCAR N/A
- CANF N/A
- Revenue
- UCAR $6,067,871.00
- CANF $560,000.00
- Revenue This Year
- UCAR N/A
- CANF $461.72
- Revenue Next Year
- UCAR N/A
- CANF N/A
- P/E Ratio
- UCAR N/A
- CANF N/A
- Revenue Growth
- UCAR 124.09
- CANF N/A
- 52 Week Low
- UCAR $1.74
- CANF $0.63
- 52 Week High
- UCAR $9.43
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- UCAR 36.07
- CANF 29.23
- Support Level
- UCAR $1.92
- CANF $0.64
- Resistance Level
- UCAR $2.15
- CANF $0.68
- Average True Range (ATR)
- UCAR 0.13
- CANF 0.03
- MACD
- UCAR 0.06
- CANF 0.01
- Stochastic Oscillator
- UCAR 56.16
- CANF 2.00
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).